The IST-3 Collaborative Group. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial IST-3): a randomised controlled trial. Lancet2012; 379:2352–63.
2.
SaverJ.L.Clinical impact of NXY-059 demonstrated in the SAINT I trial: derivation of number needed to treat for benefit over entire range of functional disability. Stroke2007; 38:1515–8.
3.
HackeW.KasteM.FieschiC.; for the Second European-Australian Acute Stroke Study Investigators. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet1998; 352:1245–51.
4.
LydenP.In anticipation of International Stroke Trial-3 (IST-3). Stroke2012; 43:1691–4.
5.
The ATLANTIS, ECASS and NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet2004; 363:768–74.
6.
HackeW.KasteM.BluhmkiE.; for the ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med2008; 359:1317–29.
7.
ClarkW.M.WissmanS.AlbersG.W.JhamandasJ.H.MaddenK.P.HamiltonS.Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS study: a randomized controlled trial. JAMA1999; 282:2019–26.
8.
Del ZoppoG.J.SaverJ.L.JauchE.C.AdamsH.P.J.Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. Stroke2009; 40:2945–8.
9.
LiebeskindD.S.Reversing stroke in the 2010s: lessons from desmoteplase in acute ischemic stroke-2 (DIAS-2). Stroke2009; 40:3156–8.
10.
WarachS.Al-RawiY.FurlanA.J.Refinement of the MR diffusion-perfusion mismatch concept for thrombolytic patient selection: insights from the desmoteplase in acute stroke trials. Stroke2012; 43:A2600.
11.
MuirK.W.Heterogeneity of stroke pathophysiology and neuroprotective clinical trial design. Stroke2002; 33:1545–50.
12.
MishraN.K.AlbersG.W.DavisS.M.Mismatch-based delayed thrombolysis: a meta-analysis. Stroke2010; 41:e25–e33.
13.
SaverJ.L.AlbersG.W.DunnB.JohnstonK.C.FisherM., for the STAIR VI Consortium. Stroke Therapy Academic Industry Roundtable (STAIR) Recommendations for extended window acute stroke therapy trials. Stroke2009; 40:2594–600.
